Longitudinal changes in antipsychotic dose in patients treated with long-acting injectable second-generation antipsychotics.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
26
1
2021
medline:
24
12
2021
entrez:
25
1
2021
Statut:
ppublish
Résumé
Only a few studies have investigated changes in the dose of long-acting injectable second-generation antipsychotics (LAI-SGAs) over the long term in the maintenance treatment of schizophrenia. In this retrospective cohort study, we examined longitudinal changes in antipsychotic dose over a 3-year period in patients with schizophrenia who had been taking LAI-SGAs for at least 1 year. We compared the total daily chlorpromazine equivalent dose of antipsychotics at 12, 24 and 36 months with the baseline dose at 3 months after initiation of LAI-SGAs. We also performed multiple regression analysis to explore factors associated with change in total daily dose 12 months after treatment initiation. A total of 154 patients fulfilled the inclusion criteria. There was no significant difference in total daily antipsychotic dose between 3 months and 12, 24 or 36 months after treatment initiation. Total daily dose was increased in 43 (27.9%), 31 (34.8%) and 22 patients (36.7%) at 12, 24 and 36 months, respectively. Age and total antipsychotic dose at 3 months were significantly negatively associated with change in total daily dose. Antipsychotic dose was basically unchanged during long-term treatment in patients treated with LAI-SGAs in the maintenance phase, although there was an increase in some patients.
Identifiants
pubmed: 33492011
doi: 10.1097/YIC.0000000000000347
pii: 00004850-202103000-00003
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-88Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M. (2017). Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 86:189–219.
Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. (2016). The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 77:1–24.
Hermes E, Rosenheck R. (2012). Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. Psychiatry Res. 199:1–7.
Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. (2012). Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. Int J Psychiatry Clin Pract. 16:138–142.
Ikai S, Suzuki T, Mimura M, Uchida H. (2016). Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study. Psychopharmacology (Berl). 233:4003–4010.
Inada T, Inagaki A. (2015). Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 69:440–447.
Knowles EE, David AS, Reichenberg A. (2010). Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiatry. 167:828–835.
Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. (2013). Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 150:281–288.
Margolese HC, Chouinard G, Beauclair L, Bélanger MC. (2002). Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 22:347–352.
McKean A, Monasterio E. (2015). Indications of atypical antipsychotics in the elderly. Expert Rev Clin Pharmacol. 8:5–7.
Nakata Y, Kanahara N, Iyo M. (2017). Dopamine supersensitivity psychosis in schizophrenia: concepts and implications in clinical practice. J Psychopharmacol. 31:1511–1518.
Ray WA, Chung CP, Murray KT, Hall K, Stein CM. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 360:225–235.
Ringen PA, Reponen EJ, Vedal TSJ, Andreassen OA, Steen NE, Melle I. (2019). Predictors for antipsychotic dosage change in the first year of treatment in schizophrenia spectrum and bipolar disorders. Front Psychiatry. 10:649.
Rossenu S, Cleton A, Hough D, Crauwels H, Vandebosch A, Berwaerts J, et al. (2015). Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Clin Pharmacol Drug Dev. 4:270–278.
Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, et al. (2013). Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 39:564–574.
Schoretsanitis G, Spina E, Hiemke C, de Leon J. (2018). A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol. 11:1237–1253.
Simpson GM, Lindenmayer JP. (1997). Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 17:194–201.
Takeuchi H, Suzuki T, Uchida H, Kikuchi T, Nakajima S, Manki H, et al. (2011). How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. J Psychiatr Res. 45:1083–1088.
Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H. (2020). Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Neuropsychopharmacology. 45:887–901.
Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H. (2013). Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. Int Clin Psychopharmacol. 28:261–266.
Wilson WH. (2004). A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract. 10:393–401.
Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. (2020). Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs. 34:579–598.
Yin J, Barr AM, Ramos-Miguel A, Procyshyn RM. (2017). Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review. Curr Neuropharmacol. 15:174–183.